NCT00675623View on ClinicalTrials.gov

A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease

PHASE3CompletedINTERVENTIONAL

Enrollment

598

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

December 31, 2009

Conditions

Alzheimer's Disease

Interventions

DRUG

Dimebon

Dimebon, 5 mg orally three times daily for six months

DRUG

Dimebon

Dimebon 20 mg orally three times daily for six months

DRUG

Placebo

Placebo three times daily for six months

Trial Locations (28)

11516

Cedarhurst

14620

Rochester

28655

Morganton

33009

Hallandale

33137

Miami

33161

North Miami

33351

Sunrise

33407

West Palm Beach

42003

Paducah

46260

Indianapolis

53562

Middleton

63044

St Louis

85004

Phoenix

93720

Fresno

Unknown

Costa Mesa

Rancho Mirage

Hamden

New Haven

Norwalk

Hialeah

Ann Arbor

Brooklyn

New York

Staten Island

Centerville

Norristown

Austin

02459

Newton

Sponsors

Lead Sponsor

Medivation, Inc.

All Listed Sponsors

lead

Medivation, Inc.

INDUSTRY